Analytical validation study confirms the reliability of the Oncotype DX RT-PCR assay using limited RNA from prostate needle biopsies, supporting improved treatment decisions for early-stage...
The Oncotype DX Prostate Cancer Assay, a clinical RT-PCR assay specifically designed for use with prostate needle biopsies, has been analytically validated using very limited RNA inputs. The assay requirements and analytical performance will provide physicians with test results from a robust and reliable assay which will enable improved treatment decisions for men diagnosed with early-stage prostate cancer.
No takes yet. Share an insight, caveat, or question.
Knezevic et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: